Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will likely be posting its Q2 2026 results before the market opens on Monday, May 11th. Analysts expect Enanta Pharmaceuticals to post earnings of ($0.46) per share and revenue of $17.0270 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The company had revenue of $18.62 million for the quarter, compared to analyst estimates of $16.14 million. On average, analysts expect Enanta Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Up 3.6%

Shares of Enanta Pharmaceuticals stock traded up $0.51 on Monday, hitting $14.86. The stock had a trading volume of 42,230 shares, compared to its average volume of 179,063. The stock has a market cap of $431.24 million, a price-to-earnings ratio of -4.65 and a beta of 1.01. Enanta Pharmaceuticals has a 52-week low of $4.96 and a 52-week high of $17.15. The company’s 50 day moving average price is $13.55 and its 200 day moving average price is $13.34.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of ENTA. Virtu Financial LLC acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at $220,000. Invesco Ltd. boosted its holdings in shares of Enanta Pharmaceuticals by 325.2% in the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock valued at $4,003,000 after acquiring an additional 194,113 shares in the last quarter. Krensavage Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after acquiring an additional 651,946 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $997,000. Finally, Opaleye Management Inc. purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $1,183,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ENTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Rodman & Renshaw assumed coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They set a “buy” rating and a $20.00 price target for the company. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.